ZLAB Jan 2025 7.500 call
| Previous close | 13.89 |
| Open | 13.89 |
| Bid | 11.60 |
| Ask | 15.80 |
| Strike | 7.50 |
| Expiry date | 2025-01-17 |
| Day's range | 13.89 - 13.89 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Business WireZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
SHANGHAI & CAMBRIDGE, Mass. & WALTHAM, Mass., May 20, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and Innoviva Specialty Therapeutics today announced that China’s National Medical Products Administration (NMPA) has approved Zai Lab’s New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex
GuruFocus.comInsider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
Edmondson Frazor Titus III, Chief Legal Officer of Zai Lab Ltd (NASDAQ:ZLAB), executed a sale of 10,000 shares of the company on May 14, 2024.
Business WireZai Lab Announces Participation in May and June Investor Conferences
SHANGHAI & CAMBRIDGE, Mass., May 16, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in May and June 2024:
